Floatz logo

Carboplatin

Pilomyxoid Astrocytoma

Julie KrystalSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Pilomyxoid Astrocytoma cohort.

Asset / SponsorPhaseRating
Mebendazole
Julie Krystal
Phase 1/2CCC
(+)-VINCRISTINE
Julie Krystal
Phase 1/2CCC
Irinotecan
Julie Krystal
Phase 1/2CCC
FDOPA
Erik Mittra
N/AD

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →